Search
Find the relevant literature, structured data, genetics and perturbation evidence.
KNOWLEDGE GRAPH-FIRST BIOMEDICAL INTELLIGENCE
We do the evidence work.
Scientists make the decisions.
Vexiom turns fragmented biomedical evidence into decision-ready target packages. A knowledge graph-first biomedical intelligence for target evaluation, evidence synthesis and decision-ready research packages.
01ComprehensiveRelevant evidence assembled across the sources that matter
02ContextualisedFindings interpreted in the biological setting in which they were observed
03TraceableImportant assertions linked back to their supporting evidence
The evidence work Vexiom performs
Scientists spend too much time assembling evidence instead of deciding what it means.
Modern biology produces more plausible targets than expert teams can evaluate with confidence. The hard part is no longer finding another hypothesis. It is building a rigorous, reproducible view of the evidence around each one.
Reconcile
Resolve aliases, identifiers, duplicated claims and inconsistent annotations.
Contextualise
Compare findings across tissue, cell type, disease, model, assay and species.
Evaluate
Assess causal strength, contradictions, uncertainty, safety and decision relevance.
Package
Turn the analysis into a clear scientific case that can be reviewed and acted on.
THE VEXIOM DIFFERENCE
A connected evidence graph, not another search tool.
Our knowledge graph-first approach connects fragmented evidence while preserving biological context, provenance and uncertainty. The result is a scientific assessment that can be reviewed, challenged and used to guide the next decision.
The product
A decision-ready target package.
A polished, structured and updateable research package that makes both the scientific case and the uncertainty explicit.
Vexiom deliverableTarget
package
package
Human evidence
Genetics, patient expression and disease relevance
Mechanism
Pathways, interactions and biological rationale
Perturbation evidence
What happened when the biology was changed
Traceability
Citations, identifiers, provenance and supporting data
Risk & contradiction
Safety signals, null results and conflicting findings
Next experiments
The studies most likely to resolve remaining uncertainty
What makes the evaluation useful
Not more information.
A clearer basis for a decision.
The evidence has value only when it is interpreted rather than merely collected.
Biological context
Findings are interpreted in the tissue, cell type, disease, experimental system, perturbation and species in which they were observed.
Causal strength
Associative findings are kept distinct from functional, perturbational and human genetic evidence.
Contradiction and uncertainty
Null results, conflicting findings and unanswered questions are surfaced rather than averaged away.
End-to-end traceability
Important claims carry provenance, confidence and the underlying evidence needed for scientific review.
How an engagement works
Engagements begin with a target, shortlist or scientific question.
Vexiom builds the evidence package.
Define the decision
We agree the target, indication, scientific question, scope and the decision the work needs to support.
Build and evaluate the evidence
Vexiom assembles the relevant evidence, evaluates it in biological context and identifies contradictions, risks and gaps.
Deliver and discuss
Vexiom delivers the target package, the evidence trail behind it and a focused discussion of the scientific implications.
TAILORED ENGAGEMENTS
In tailored engagements, Vexiom can incorporate proprietary datasets and internal experimental evidence.
Target prioritisationCompare candidates on a consistent evidence basis
Portfolio reviewReassess the scientific case as evidence evolves
Early due diligencePressure-test the evidence around an external opportunity
Experiment planningIdentify the studies that would be most decision-changing
Get in touch
Better target decisions start with better evidence.
Vexiom builds the evidence around them.
Vexiom welcomes conversations with pharmaceutical R&D teams, scientific collaborators and investors.